Pricing Log in Create free account
Sunday 18 October 2026 Export IRD’s income statement to Excel — free account

Opus Genetics, Inc.

IRD Healthcare Biotechnology

Opus Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.2 million, up 29.1% from fiscal 2024. In the quarter to June 2026, revenue fell 73.8%, EPS grew 33.3% and free cash flow fell 16.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.81 0.24 −5.93%
Market cap
$336.9M
P/E
0.0×
Fwd P/E
−3.8×
Dividend yield
—
F-score
5/9
Altman Z
−4.35
Beneish M
−4.00
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.32
Total sells 19.35
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — 1 — — — — — — — — — —
Sell — 1 — — 4 6 1 — 4 — 2 —
Insider Ownership 29.52%

Capital & Financial Ratios $m

Market Cap 336.94
Revenue 9.86
Net Income (107.61)
Free Cash Flow (40.67)
Net Debt (53.88)
Current Ratio 12.19 (at or above 1.5: strong)
Debt/Equity (2.69) (negative: negative equity)
P/E ratio 0.00
Fwd P/E (3.81) (negative: loss-making)
P/S ratio 36.91 (above 10: high)
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth (29.71%) (below 0%: weak)
Next Y EPS Growth 32.14% (at or above 15%: strong)
Next Y revenue growth (13.50%) (below 0%: weak)
Next 5Y EPS Growth 33.40% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 31.5×, against a ten-year median of 11.9×; over the ten years it ranged from −0.9× in 2024 to 44.0× in 2021.
P/S against its own 10 years 83.17%
10-year low 10-year high
EV/Sales against its own 10 years 88.20%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 51 30 45 89
Receivables 1 4 2 1
Inventory — — — —
Other 1 2 1 0
54 37 50 93
2023 2024 2025 Q'26
Payables 2 3 3 2
ST’ Debt — — — —
Other 0 0 — —
4 11 8 8

Compound Annual Growth %

10y 5y 3y
Sales — — (29.11%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (2.00%) 0.00% (30.76%)

Revenue $m

Mar Jun Sep Dec Year
’26 2 1 — — —
’25 4 3 3 4 14
’24 2 1 4 4 11
’23 2 4 12 2 19
’22 — — — 40 40
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) (12) — — —
’25 (9) (10) (6) (10) (35)
’24 (6) (7) (5) (7) (26)
’23 (4) 1 (3) 5 (1)
’22 (6) (4) (4) 29 14
’21 (6) (4) (4) (6) (19)
’20 (1) (1) (1) (4) (7)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) (12) — — —
’25 (9) (10) (6) (10) (35)
’24 (6) (7) (5) (7) (26)
’23 (4) 1 (3) 5 (1)
’22 (6) (4) (4) 29 14
’21 (6) (4) (4) (6) (19)
’20 (1) (1) (1) (6) (8)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.75) (0.07) — — —
’25 (0.24) (0.12) (0.25) (0.21) (0.80)
’24 (0.29) (0.30) (0.29) (1.27) (2.15)
’23 (0.28) (0.24) 0.25 (0.21) (0.46)
’22 (0.35) (0.25) (0.22) 1.58 0.87
’21 (3.57) (0.52) (0.25) (0.35) (3.82)
’20 (0.87) (0.43) (0.33) (3.65) (5.28)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 62.40 67.20 40.80 6.24 3.68 3.19 1.78 2.55 0.81 0.65

Analyst estimates 2026–2028

Powerpack
High 201.60 340.80 129.60 79.20 17.04 13.81 4.43 6.60 3.40 2.59
People
People Employees 20 17 10 5 5 8 9 14 18 28
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.07 4.43 1.36 0.61 0.51
Income, $m
Income, $m Revenue — — — — — 1 40 19 11 14
Gross margin, % — — 0.00 0.00 0.00 100.00 100.00 100.00 100.00 100.00
EBT (9) (25) (14) (6) (25) (57) 18 (10) (58) (50)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 (9,625.30) 45.68 (52.36) (523.40) (349.33)
Net income (9) (25) (14) (6) (25) (57) 18 (10) (58) (50)
Depreciation 0 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.04 2.00 0.88 0.41 0.23
Earnings (19.21) (44.18) (21.13) (2.17) (5.28) (3.82) 0.90 (0.46) (2.15) (0.80)
Cash flow (29.21) (27.03) (27.51) (1.26) (1.46) (1.30) 0.72 (0.05) (0.96) (0.57)
Capex (0.02) (0.13) (0.06) (0.01) (0.32) (0.01) 0.00 0.00 0.00 0.00
Free cash flow (29.23) (27.17) (27.57) (1.27) (1.77) (1.31) 0.72 (0.05) (0.96) (0.57)
Book value 37.67 29.40 15.42 (2.66) (2.89) 1.50 2.32 2.31 0.25 0.25
Shares, m 0 1 1 3 5 15 20 22 27 62
Valuation, ×
Valuation, × P/E — — — — — 0.00 4.33 0.00 0.00 0.00
P/S — — — — — 31.86 1.73 3.48 2.89 8.81
P/B — — — — — 2.49 1.51 1.33 4.73 8.15
EV/Sales — — — — — 17.95 0.68 0.84 0.16 5.72
EV/FCF — — — — — (1.49) 2.16 (5.93) (0.06) (2.21)
Cash, $m
Cash, $m Operating cash flow (13) (15) (19) (4) (7) (19) 14 (1) (26) (35)
Capex 0 0 0 0 (1) 0 — — — —
Free cash flow (13) (15) (19) (4) (8) (19) 14 (1) (26) (35)
Balance, $m
Balance, $m Working capital 19 25 13 (8) 14 22 46 50 25 42
Total debt — — — 6 — 1 — — — —
Net debt (20) (27) (15) 4 (16) (24) (43) (51) (30) (45)
Shareholders’ equity 17 17 11 (8) (13) 22 46 50 7 15
Returns, %
Returns, % ROA (40.60) (102.55) (64.82) (69.21) (252.95) (259.11) 47.66 (19.40) (126.71) (113.86)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 320.34 0.00 0.00 0.00
ROE (51.95) (149.55) (105.14) (410.87) 234.18 (1,295.10) 52.26 (20.77) (203.19) (449.36)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Opus Genetics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
FENC Adherex Technologies Inc. $362.9M — (loss-making) 31.4× +85.18% (above 0%: growing) n/m +101.36% (above 0%: growing) 95.97% 9.72% Compare
TTRX Turn Therapeutics Inc. $345.3M — (loss-making) — — n/m −74.76% (below 0%: shrinking) — 0.00% Compare
OBIO Orchestra BioMed Holdings, Inc. $345.0M — (loss-making) — (loss-making) −89.47% (below 0%: shrinking) n/m −25.87% (below 0%: shrinking) 71.59% (25,404.55%) Compare
CCCC C4 Therapeutics, Inc. $342.0M — (loss-making) — (loss-making) +2.75% (above 0%: growing) n/m +86.84% (above 0%: growing) 100.00% (397.88%) Compare
RLMD Relmada Therapeutics, Inc. $341.3M — (loss-making) — — n/m −50.06% (below 0%: shrinking) 0.00% 0.00% Compare
IRD Opus Genetics, Inc. $336.9M — (loss-making) — (loss-making) −73.80% (below 0%: shrinking) n/m −16.37% (below 0%: shrinking) 100.00% (2,182.78%)
ENTA Enanta Pharmaceuticals, Inc. $334.1M — (loss-making) — (loss-making) −21.60% (below 0%: shrinking) n/m −157.51% (below 0%: shrinking) 100.00% (120.04%) Compare
CYPH Cypherpunk Technologies Inc. $325.5M 4.4× — (loss-making) 0.00% n/m +15.53% (above 0%: growing) 0.00% 0.00% Compare
ARCT Arcturus Therapeutics Holdings Inc. $320.3M — (loss-making) — (loss-making) −89.54% (below 0%: shrinking) n/m −245.65% (below 0%: shrinking) 100.00% (863.30%) Compare
Median of peers $341.7M — — −10.80% — −37.97% 95.97% (60.02%)

All 614 Biotechnology stocks →

Opus Genetics, Inc. (IRD) key facts

  • Strength: Opus Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.2 million, up 29.1% from fiscal 2024.
  • Opus Genetics, Inc. (IRD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, IRD traded at $3.81, a market capitalization of $336.9 million.
  • Return on equity was −449.4% and debt-to-equity -2.69.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −4.35 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Opus Genetics, Inc. (IRD) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/IRD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com